Search Results

You are looking at 91 - 100 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management

Presented by: Gabriela S. Hobbs and Christopher Bell

preferred. Imatinib should be paused in cases of hematologic toxicities such as neutropenia or thrombocytopenia. After recovery from these toxicities, it can be resumed at the initial dose for first incidences, but in cases of recurrence, the dose should

Full access

Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer

Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess

regimens; (4) any other grade 3 nonhematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome but excluding alopecia; (5) grade 4 thrombocytopenia; (6) any grade 4 neutropenia lasting more than 7 days (as defined by the NCI

Full access

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro, and Gary H. Lyman

descriptive review . Nat Clin Pract Oncol 2007 ; 4 : 643 – 656 . 29. Kuderer NM Dale DC Crawford J . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer 2006 ; 106 : 2258 – 2266 . 30

Full access

CDK4/6 Inhibitors for Advanced Hormone Receptor–Positive Breast Cancer, 2019 and Beyond

Rachel M. Layman

. Neutropenia of all grades was observed in 88.5% of patients, 5 similar to the approximately 80% reported in PALOMA-2 and PALOMA-3. 2 , 3 Interestingly, there was less grade 3/4 neutropenia in this study (41.5% 5 vs 66.4% and 65% in PALOMA-2 2 and PALOMA-3

Full access

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann, and Courtney Smith

There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. In certain instances, the cancer itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized as a major

Full access

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non–Small Cell Lung Cancer

John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino, and Dwight Owen

, peritoneal nodules and ascites (Fig. 1). 3 months after starting dab/tram, CT scans showed reduction in size and number of pulmonary masses and resolution of ascites. Adverse effects included transient grade 3 neutropenia and grade 1 thrombocytopenia which

Full access

CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup

Carlo Signorelli, Federica Zoratto, Donatello Gemma, Rosa Saltarelli, Maria Grazia Morandi, Roberta Grande, Gian Paolo Spinelli, Salvatore De Marco, Isabella Sperduti, Mario Giovanni Chilelli, Anna Ceribelli, and Enzo Maria Ruggeri

, 40% treated with REG and 60% with FTD/TPI, were also analyzed. In this subgroup, the most common grade 3/4 AE was hand-foot syndrome (33.3%) vs neutropenia (42.8%), the mOS was 3.5 vs 5 months and the best response was stable disease (35.7% vs 14

Full access

Biosimilars: Are They Ready for Primetime in the United States?

Bradford R. Hirsch and Gary H. Lyman

, providing an excellent example of the strengths and weaknesses of the field. These agents are administered subcutaneously, starting 1 to 3 days after completion of cytotoxic therapy to reduce the severity and duration of neutropenia and the risk of febrile

Full access

Optimizing BTK Inhibition in Waldenström Macroglobulinemia

Shayna Sarosiek and Jorge J. Castillo

ibrutinib also had similar adverse effects. 10 The most common grade ≥3 adverse events of acalabrutinib in patients with WM included neutropenia, pneumonia, lower respiratory infection, anemia, and hyponatremia. 17 The most common grade ≥3 adverse events

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, and Hema Sundar

, for patients treated with ibrutinib and chlorambucil. Neutropenia (13%), pneumonia (12%), hypertension (8%), and anemia (7%) were the common grade ≥3 adverse events. Ibrutinib also improved PFS compared with chlorambucil in patients with high-risk CLL